225 related articles for article (PubMed ID: 19007374)
1. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
[TBL] [Abstract][Full Text] [Related]
2. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
[TBL] [Abstract][Full Text] [Related]
3. Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing.
Park JY; Yoon S; Park MS; Cho DY; Park HS; Moon du G; Yoon DK
J Korean Med Sci; 2011 Jan; 26(1):85-91. PubMed ID: 21218035
[TBL] [Abstract][Full Text] [Related]
4. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
6. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
7. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
Zhu XD; Zheng A; Wang ZQ; Shao Q
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
[TBL] [Abstract][Full Text] [Related]
8. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
9. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
[TBL] [Abstract][Full Text] [Related]
11. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
12. Adaptation of the prostate biopsy collaborative group risk calculator in patients with PSA less than 10 ng/ml improves its performance.
Stojadinovic M; Trifunovic T; Jankovic S
Int Urol Nephrol; 2020 Oct; 52(10):1811-1819. PubMed ID: 32468165
[TBL] [Abstract][Full Text] [Related]
13. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
14. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
[TBL] [Abstract][Full Text] [Related]
15. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Ngo TC; Turnbull BB; Lavori PW; Presti JC
J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
[TBL] [Abstract][Full Text] [Related]
16. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Thompson IM; Ankerst DP; Chi C; Goodman PJ; Tangen CM; Lucia MS; Feng Z; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Apr; 98(8):529-34. PubMed ID: 16622122
[TBL] [Abstract][Full Text] [Related]
17. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
18. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.
Auffenberg GB; Merdan S; Miller DC; Singh K; Stockton BR; Ghani KR; Denton BT
Urology; 2017 Jun; 104():137-142. PubMed ID: 28237530
[TBL] [Abstract][Full Text] [Related]
20. The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population.
Lienert AR; Davidson PJ; Wells JE
N Z Med J; 2009 Jan; 122(1288):39-49. PubMed ID: 19182841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
